HER2 positive breast carcinoma

Related records

Broader conditions (17)

• Breast cancer
• Breast carcinoma
• Breast carcinoma by gene expression profile
• Breast disorder
• Breast neoplasm
• Cancer
• Cancer or benign tumor
• Carcinoma
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Epithelial neoplasm
• Human disease
• Neoplasm
• Neoplasm of thorax
• Neoplastic disease or syndrome
• Thoracic cancer

Narrower conditions (1)

• Triple-positive breast carcinoma

Trials (458)

• 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
• 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
• 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
• 99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy
• A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
• A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
• A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer
• A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
• A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
• A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer
• A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer
• A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
• A Phase 1/1b Study of IAM1363 in HER2 Cancers
• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
• A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
• A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
• A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
• A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
• A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin
• A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

Approved drugs (14)

• Abemaciclib
• Capecitabine
• Cyclophosphamide
• Doxorubicin hydrochloride
• Fulvestrant
• Lapatinib ditosylate
• Paclitaxel
• Palbociclib
• Pertuzumab
• Tamoxifen citrate
• Trastuzumab
• Trastuzumab deruxtecan
• Trastuzumab emtansine
• Tucatinib

Drugs in development (15)

• .ALPHA.-tocopheryloxyacetic acid Phase 1
• Carboplatin Phase 3
• Cixutumumab Phase 2
• Docetaxel Phase 3
• Lapatinib Phase 3
• Nebivolol Phase 2
• Neratinib Phase 3
• Niraparib Phase 3
• Poziotinib Phase 2
• Rifaximin Phase 2
• Trastuzumab botidotin Phase 3
• Trastuzumab envedotin Phase 3
• Utomilumab Phase 2
• Vinorelbine Phase 3
• Zenidolol Phase 3

Other linked drugs (3)

• Anvatabart opadotin
• Margetuximab
• Pyrotinib